-
Jun.122023NEWS
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson’s Disease
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Oppo..
-
May.252023NEWS
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson’s Disease
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmac..
-
May.242023NEWS
HanAll Biopharma, Conclusion of Joint Development Contract for New Medicine of Dry Eye Disease with Daewoong Pharmaceutical
HanAll Biopharma, Conclusion of Joint Development Contract for New Medicine of Dry Eye Disease with ..
-
May.192023NEWS
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-control..
-
Apr.282023NEWS
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
-
Mar.292023NEWS
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth